A Phase I, Open-label, Single-dose Trial to Investigate Metabolism and Pharmacokinetics of BI 730357 BS (C-14) Administered as Oral Solution in Healthy Male Volunteers
Latest Information Update: 13 Jul 2023
At a glance
- Drugs BI 730357 (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 16 Nov 2018 Status changed from active, no longer recruiting to completed.
- 24 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 17 Sep 2018 New trial record